REGENXBIO, Inc. IPO Research Information

REGENXBIO, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on REGENXBIO, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
REGENXBIO, Inc.	RGNX - NASDAQ	$17.00-$19.00	$22.00	$30.26	6.3 million	9/17/2015
Underwriter(s): Morgan Stanley, BofA Merrill Lynch, Piper Jaffray
Co-Manager(s): Chardan Capital Markets
Industry: Health Care
Filing(s): Filed 2015-08-17 Terms Added 2015-09-08

REGENXBIO, Inc. Quote & Chart - Click for current quote - RGNX

About REGENXBIO, Inc. (adapted from REGENXBIO, Inc. prospectus):
They are a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "RGNX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.